Profile data is unavailable for this security.
About the company
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
- Revenue in USD (TTM)0.00
- Net income in USD-16.73m
- Incorporated2017
- Employees4.00
- LocationAcurx Pharmaceuticals Inc259 Liberty AvenueSTATEN ISLAND 10305United StatesUSA
- Phone+1 (917) 533-1469
- Fax+1 (302) 636-5454
- Websitehttps://www.acurxpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 27.93m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Lipocine Inc | 4.80m | -8.49m | 28.50m | 17.00 | -- | 1.34 | -- | 5.94 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| IGC Pharma Inc | 1.06m | -13.30m | 28.74m | 67.00 | -- | 3.65 | -- | 27.06 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 28.92m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 29.06m | 20.00 | -- | 2.26 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 29.44m | 57.00 | -- | 0.6384 | -- | 10.59 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 29.65m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 29.68m | 4.00 | -- | 4.78 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 29.89m | 4.00 | -- | 8.59 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 30.24m | 1.00 | -- | 1.30 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.45m | 30.93m | 32.00 | -- | 0.521 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Dyadic International Inc | 1.80m | -7.74m | 30.95m | 7.00 | -- | 9.77 | -- | 17.16 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 31.16m | 23.00 | -- | 1.40 | -- | 25.35 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Iterum Therapeutics PLC | 0.00 | -28.34m | 31.56m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Surrozen Inc | 0.00 | -53.45m | 31.69m | 42.00 | -- | 5.16 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Acurx Pharmaceuticals Inc's reporting currency: US Dollar USD
7.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 491.69k | 3.03% |
| Prospect Financial Services LLCas of 30 Sep 2024 | 295.08k | 1.82% |
| Geode Capital Management LLCas of 30 Jun 2024 | 130.02k | 0.80% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 46.40k | 0.29% |
| LPL Financial LLCas of 30 Sep 2024 | 44.78k | 0.28% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 43.47k | 0.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 27.29k | 0.17% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 25.22k | 0.16% |
| NBC Securities, Inc.as of 30 Sep 2024 | 19.00k | 0.12% |
| TD Waterhouse Canada, Inc.as of 30 Jun 2024 | 18.66k | 0.12% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
